CSPC PHARMACEUT.GR. ADR4 Total Liabilities
CSPC PHARMACEUT.GR. ADR4 total liabilities. Based on the latest financial reports, CSPC PHARMACEUT.GR. ADR4 (CVGU) has total liabilities worth €16.59 Billion EUR (≈ $19.40 Billion USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CSPC PHARMACEUT.GR. ADR4 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of CSPC PHARMACEUT.GR. ADR4 (2021–2025)
Total liabilities of CSPC PHARMACEUT.GR. ADR4 from 2021 to 2025. This chart illustrates how CSPC PHARMACEUT.GR. ADR4's total liabilities have evolved over time, based on quarterly financial data.
CSPC PHARMACEUT.GR. ADR4 Competitors by Total Liabilities
The table below lists competitors of CSPC PHARMACEUT.GR. ADR4 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mankind Pharma Ltd
NSE:MANKIND
|
India | Rs-165.61 Billion |
|
Tempus AI, Inc. Class A Common Stock
NASDAQ:TEM
|
USA | $1.92 Billion |
|
WOORI FIN. GRP SP.ADR/3
F:2WGA
|
Germany | €563.60 Trillion |
|
Elanco Animal Health
NYSE:ELAN
|
USA | $6.97 Billion |
|
Align Technology Inc
NASDAQ:ALGN
|
USA | $2.16 Billion |
|
Applied Industrial Technologies
NYSE:AIT
|
USA | $1.13 Billion |
|
HDFC Asset Management Company Limited
NSE:HDFCAMC
|
India | Rs7.63 Billion |
|
REXEL S.A. ADR EO 5
F:E7V0
|
Germany | €8.96 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down CSPC PHARMACEUT.GR. ADR4's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see CVGU asset base.
Liquidity & Leverage Metrics
CSPC PHARMACEUT.GR. ADR4 Total Liabilities Ratios Explained
CSPC PHARMACEUT.GR. ADR4 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CSPC PHARMACEUT.GR. ADR4's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CSPC PHARMACEUT.GR. ADR4 (2021–2025)
The table below shows the annual total liabilities of CSPC PHARMACEUT.GR. ADR4 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €12.15 Billion ≈ $14.20 Billion |
+15.44% |
| 2024-12-31 | €10.52 Billion ≈ $12.30 Billion |
-6.58% |
| 2023-12-31 | €11.26 Billion ≈ $13.17 Billion |
+11.22% |
| 2022-12-31 | €10.13 Billion ≈ $11.84 Billion |
+27.99% |
| 2021-12-31 | €7.91 Billion ≈ $9.25 Billion |
-- |
About CSPC PHARMACEUT.GR. ADR4
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining cap… Read more